MedTrace Logo

Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

NCT00287976 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well irinotecan works in treating young patients with refractory or recurrent hepatoblastoma.

Conditions

Interventions

DRUG

irinotecan hydrochloride

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Jozsef Zsiros, MD, PhD · Emma Kinderziekenhuis

  • Laurence Brugieres, MD · Gustave Roussy, Cancer Campus, Grand Paris

  • Penelope Brock, MD, PhD · Great Ormond Street Hospital for Children NHS Foundation Trust

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2008-12-31

Countries

  • Ireland
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287976 on ClinicalTrials.gov